Talk:Autism spectrum: Difference between revisions
>David Hedlund Added https://www.ncbi.nlm.nih.gov/pubmed/30196397 |
>David Hedlund sort |
||
Line 2: | Line 2: | ||
{{for|substances|Cannabinoid}} | {{for|substances|Cannabinoid}} | ||
===Biology=== | |||
* [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4604173/ Endocannabinoid Signaling in Autism] | * [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4604173/ Endocannabinoid Signaling in Autism] | ||
* [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5618565/ The Endocannabinoid System and Autism Spectrum Disorders: Insights from Animal Models] | * [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5618565/ The Endocannabinoid System and Autism Spectrum Disorders: Insights from Animal Models] | ||
* [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5535348/ Role of Endocannabinoids on Neuroinflammation in Autism Spectrum Disorder Prevention] | * [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5535348/ Role of Endocannabinoids on Neuroinflammation in Autism Spectrum Disorder Prevention] | ||
* [https://www.ncbi.nlm.nih.gov/pubmed/28880200 The Endocannabinoid System and Autism Spectrum Disorders: Insights from Animal Models.] | * [https://www.ncbi.nlm.nih.gov/pubmed/28880200 The Endocannabinoid System and Autism Spectrum Disorders: Insights from Animal Models.] | ||
===Pharmacotherapy=== | |||
* [https://www.ncbi.nlm.nih.gov/pubmed/30171992 Cannabidiol as a suggested candidate for treatment of autism spectrum disorder.] | |||
==Serotonin== | ==Serotonin== | ||
{{for|substances|Serotonin}} | {{for|substances|Serotonin}} | ||
===Biology=== | |||
* [https://www.ncbi.nlm.nih.gov/m/pubmed/16648340/ Cortical serotonin 5-HT2A receptor binding and social communication in adults with Asperger's syndrome: an in vivo SPECT study.] | * [https://www.ncbi.nlm.nih.gov/m/pubmed/16648340/ Cortical serotonin 5-HT2A receptor binding and social communication in adults with Asperger's syndrome: an in vivo SPECT study.] | ||
* [http://www.ncbi.nlm.nih.gov/pubmed/20150873 Elevated urine levels of bufotenine in patients with autistic spectrum disorders and schizophrenia.] | * [http://www.ncbi.nlm.nih.gov/pubmed/20150873 Elevated urine levels of bufotenine in patients with autistic spectrum disorders and schizophrenia.] | ||
===Pharmacotherapy=== | |||
* [https://www.ncbi.nlm.nih.gov/pubmed/17608329 Flashback to the 1960s: LSD in the treatment of autism.] | * [https://www.ncbi.nlm.nih.gov/pubmed/17608329 Flashback to the 1960s: LSD in the treatment of autism.] | ||
===Entacogens=== | ====Entacogens==== | ||
* [https://www.ncbi.nlm.nih.gov/pubmed/25818246 MDMA-assisted therapy: A new treatment model for social anxiety in autistic adults.] | * [https://www.ncbi.nlm.nih.gov/pubmed/25818246 MDMA-assisted therapy: A new treatment model for social anxiety in autistic adults.] | ||
* [https://www.ncbi.nlm.nih.gov/pubmed/30196397 Reduction in social anxiety after MDMA-assisted psychotherapy with autistic adults: a randomized, double-blind, placebo-controlled pilot study.] | * [https://www.ncbi.nlm.nih.gov/pubmed/30196397 Reduction in social anxiety after MDMA-assisted psychotherapy with autistic adults: a randomized, double-blind, placebo-controlled pilot study.] |